Generalizability of Clinical Trials of Novel Weight Loss Medications to the US Adult Population
JAMA Internal Medicine
•
November 25, 2024
How generalizable are GLP-1 weight-loss trials to U.S. adults?
About one-third of U.S. adults eligible per FDA labeling for GLP-1/GLP-1–GIP weight-loss drugs would have been excluded from the pivotal trials supporting these medications.
- Level of evidence
- Level IV (cross-sectional observational study).
- DocG quality score
- 3.7 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
